news, journals and articles from all over the world.
Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will showcase a diverse range of hematology/oncology data from their clinical research program at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and online) from December 7-10, 2024.
Hematology researchers from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami are authors or co-authors on more than 70 posters to be presented at the Annual Meeting & Exposition of the American Society of Hematology in San Diego, Dec. 7-10. Links to each abstract are included in this tip sheet.
Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami will be presented at the Annual Meeting & Exposition of the American Society of Hematology in San Diego, Dec. 7-10.
Blood cancers are a type of cancer that affects the blood and blood cells, and are caused by DNA mutations that cause abnormal blood cell behavior. Blood cancers are more common in men than women, and account for about 10% of…
Expert sources and news tips from Sylvester Comprehensive Cancer Center for Blood Cancer Awareness Month in September.
A Cleveland Clinic study recently published in Blood Cancer Journal evaluated factors associated with delayed time to treatment with oral antimyeloma medications in patients with newly diagnosed multiple myeloma. The research found a significant delay in the initiation of these more costly medications compared…
Exciting research at the frontier of artificial intelligence and data science in laboratory medicine was presented today at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo).
Factor Bioscience Inc., a Cambridge, Massachusetts-based biotechnology company pioneering mRNA-based cell engineering, today announced that the United States Patent and Trademark Office (USPTO) has terminated three separate ex parte reexaminations of three U.S. patents owned by Factor.
In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS). This prestigious distinction stands as one of the highest accolades within the scientific research community.
Using a trial of persons with monoclonal gammopathy of undetermined significance (MGUS), researchers developed a prediction model that accurately predicts the presence of 10 percent or more bone marrow plasma cells (BMPC) and therefore a diagnosis of smoldering multiple myeloma (SMM) or multiple myeloma (MM) by bone marrow criteria in persons presumed to have MGUS.
A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.
Professor Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore at the National University of Singapore, together with Assistant Professor Tobias Janowitz, Principal Investigator at the Cold Spring Harbor Laboratory in New York, and an international group of researchers from the USA and UK, have discovered that ketogenic diets delay tumour growth but accelerate cachexia, a wasting syndrome, an unintended side effect that could cause death.
Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.
The Myeloma Research Institute’s launch follows many important accomplishments by C. Ola Landgren, M.D., Ph.D. and his team, who are dedicated to fulfilling a promise of providing the best cancer care to myeloma patients. Florida is among the states with the highest rates of new myeloma diagnoses in the U.S., with 7.9 cases diagnosed in every 100,000 of the state’s residents.
Australian researchers will use new technology to improve the diagnosis and treatment of blood cancers, which affect 1.24 million people globally, including 720,000 who die from leukemia, lymphoma or myeloma each year.
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published today in Blood Advances.
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
In a study published in Nature Communications, researchers at Sylvester Comprehensive Cancer Center have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma, progress to full-blown cancer
DALLAS – March 8, 2021 – A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.
Dr. Cherry focused on results from a Juno Therapeutics phase 2 study of liso-cel, an investigational CAR T therapy being tested against aggressive relapsed/refractory B cell non-Hodgkin lymphoma. Early results indicate a good safety profile, with few adverse events reported. Dr. Cherry also presented on the final results of a phase 1 study of targeted therapy gilteritinib in newly diagnosed acute myeloid leukemia (AML). Gilteritinib targets the most common mutation that causes AML, the FLT3 gene. Gilteritinib is sold under the brand name Xospata® by Astellas Pharma.
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
— A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
As we celebrate National Nurses Week, Memorial Sloan Kettering Cancer Center (MSK) and The Robbins Family Foundation recognize seven distinguished nursing staff members for their exemplary service. Each member of this select group is being honored with the inaugural 2020 Robbins Family Award for Nursing Excellence.
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu